Skip to main content

Private equity

Sofinnova Partners grows crossover fund by 63% to €725m, eyes European life sciences funding gap

Monday, November 16, 2026 · first reported by AltAssets and 4 others

Sofinnova Partners has closed Sofinnova Crossover II at €725 million ($815 million per HedgeCo), above its original target. AltAssets puts the fund at 63% larger than its predecessor.

The vehicle will hold about 15 companies, mainly European clinical-stage biopharma and medtech businesses needing capital to reach commercialization, with some investments in the United States and elsewhere. Partner Kinam Hong said about 80% will go to Europe. Investing has begun, with Neurent Medical, Hemab Therapeutics and CellCentric among the first holdings.

Size
€725M (≈$789M)
Stage
Target
Asset class
Private equity, Venture
Geography
Europe

In the data This close in the fund closes table · Every Sofinnova close

The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.

See an error?

Coverage

5 sources

Got news? Send it to us →